2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 73

Regulation of Th17 Cell Responses By IL-25
Abstract Number: 74

IL-17 Blockade Attenuates Osteoblastic Activity and Differentiation in Ankylosing Spondylitis
Abstract Number: 75

Factors Associated with TNF Receptor 2 Levels Above the Measurable Range in Rheumatoid Arthritis
Abstract Number: 76

TNF-α Potentiates Uric Acid-Induced Interleukin-1β Secretion in Human Neutrophils
Abstract Number: 77

Platelets Induce IL-1b Production in Human Monocytes through NLRP3 Inflammasome Activation
Abstract Number: 78

IL-37 Is Associated with Increased Atherogenesis in Patients with Rheumatoid Arthritis
Abstract Number: 79

Functional Analysis of the Novel G58V Mutation in the TNFRSF1A Gene Identified in a Family with TNF Receptor-Associated Periodic Syndrome (TRAPS)
Abstract Number: 80

Production and Characterization of Human Interferon-Epsilon and Interferon-Kappa to Investigate Their Potential Role in Lupus
Abstract Number: 81

Selective Inhibition of the Immunoproteasome Subunit LMP7 Is Not Sufficient for Blocking Cytokine Production or Attenuating Progression of Experimental Arthritis
Abstract Number: 82

CKD-506, a Novel Inhibitor of Histone Deacetylase 6 (HDAC6) Has a Therapeutic Potential in Rheumatoid Arthritis and Inflammatory Bowel Disease
Abstract Number: 83

Whole Blood Stimulations Identify Elevated T Cell Cytokines and Altered Granulocyte/Dendritic Cell Signaling in SLE Patients with Variable Disease Activity
Abstract Number: 84

Physiological Autoantibodies Against the Endthelin Receptor Type-a Are Critically Involved in the Homeostasis of Immune Cells
Abstract Number: 85

Enhanced IFN-γ STAT1 Signaling in CD4 T Cell Populations and Attenuated IL-2 STAT5 Signaling Contribute to the Pathogenesis of Rheumatoid Arthritis (RA)
Abstract Number: 86

Regulation of Interleukin-1β Signaling By Inhibition of O-Glc-Nacase in Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 87

A Novel Histone Deacetylase 6 Inhibitor, CKD-M808, Regulates the Adhesion and Migration of Fibroblast-like Synoviocytes, and Enhances Suppressive Function of Regulatory T Cells in Rheumatoid Arthritis

« Previous Page
1
…
5
6
7
8
9
…
201
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].